Skip to main content

Advertisement

Table 4 Adverse events

From: Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: a prospective, multicenter, open-label, single-arm phase II study

n (%) Any grade Grade 3 Grade 4
Anemia 51 (48%) 0 1 (1%)
Neutropenia 42 (39%) 8 (7%) 1 (1%)
Leukopenia 45 (42%) 0 1 (1%)
Thrombocytopenia 46 (43%) 2 (2%) 1 (1%)
AST increased 49 (46%) 0 0
ALT increased 37 (35%) 1 (1%) 0
Hand-foot syndrome 32 (30%) 2 (2%) 0
Peripheral sensory neuropathy 69 (64%) 10 (9%) 0
Loss of appetite 28 (26%) 3 (3%) 0
General fatigue 25 (23%) 2 (2%) 0
Nausea 26 (24%) 2 (2%) 0
Vomiting 8 (7%) 3 (3%) 0
Diarrhea 19 (18%) 4 (4%) 0
Allergy 6 (3%) 2 (2%) 0